業績集
- Assessment of postoperative therapy de-escalation for early-stage, intermediate-risk cervical cancer.
Matsuo K, Shimada M, Matsuzaki S, Machida H, Shigeta S, Yoshida H, Kato K, Kanao H, Takekuma M, Mikami M, Okamoto A.
Int J Gynecol Cancer. 2024 Aug 6:ijgc-2024-005597. doi: 10.1136/ijgc-2024-005597. Online ahead of print. PMID: 39107048
- Heterogeneous treatment effects of adjuvant therapy for patients with cervical cancer in the intermediate-risk group
Taguchi A, Kato K, Hara K, Furusawa A, Nakajima Y, Ishizawa C, Tanikawa M, Sone K, Mori M, Shimada M, Okamoto A, Takekuma M
Cancer Med. 2023;00:1-11. doi:10.1002/cam4.6460
- Clinicopathological demographics of malignant melanomas of the vulva and vagina in Japan
Ogata D, Nishio S, Hatta N, Kaji T, Fujii K, Mikami M, Kiyohara Y, Enomoto T.
Melanoma Research 33(4):p 300-308, August 2023. | DOI: 10.1097/CMR.0000000000000894.
- Current status of vulvar cancer in Japan: analysis of the Japanese Gynecologic Oncology Group nationwide survey study
Nishio S.
Jpn J Clin Oncol. 2023 Aug 7;hyad089. doi: 10.1093/jjco/hyad089.
- Surgically treated cervical cancer in a high-risk group in the era of the 2018 FIGO staging schema: a nationwide study
Shigeta S, Shimada M, Tsuji K, Watanabe Z, Tanase Y, Matsuo K, Nakanishi T, Saito T, Aoki D, Mikami M.
Sci Rep. 2023 Jul 25;13(1):12020. doi: 10.1038/s41598-023-39014-8.
- Prognostic factors of 2018 FIGO stage IB-IIA cervical cancer with absence of high/ intermediate surgical-pathological risk factors.
Shibuya Y, Shimada M, Tsuji K, Shigeta S, Tanase Y, Matsuo K, Yamaguchi S, Kanao H, Saito T, Mikami M.
Jpn J Clin Oncol. 2022 Aug 1:hyac125. doi: 10.1093/jjco/hyac125. Online ahead of print.
- Risk assessment in the patients with uterine cervical cancer harboring intermediate risk factors after radical hysterectomy: a multicenter, retrospective analysis by the Japanese Gynecologic Oncology Group
Shogo Shigeta, Muneaki Shimada, Keita Tsuji, Tomoyuki Nagai, Yasuhito Tanase, Koji Matsuo, Shoji Kamiura, Takashi Iwata, Harushige Yokota, Mikio Mikami
Int J Clin Oncol. 2022 Jun 14. doi: 10.1007/s10147-022-02198-6.
- Paclitaxel-carboplatin and bevacizumab combination with maintenance bevacizumab therapy for metastatic, recurrent, and persistent uterine cervical cancer: An open-label multicenter phase II trial (JGOG1079)
Terumi Tanigawa, Nobuhiro Takeshima, Hideki Ishikawa, Shin Nishio, Tomoka Usami, Takaharu Yamawaki, Tetsuro Oishi, Kei Ihira, Hisamori Kato, Mayako Goto, Motoaki Saito, Yusuke Taira, Masatoshi Yokoyama, Tadahiro Shoji, Eiji Kondo, Atsushi Mori, Takeshi Yokoi, Naomi Iwasa-Inoue, Yasuyuki Hirashima, Takayuki Nagasawa, Motoki Takenaka, Mikio Mikami, Toru Sugiyama, Takayuki Enomoto
Gynecol Oncol. 2022 Jun;165(3):413-419.
- Characteristics and outcomes of women with adenocarcinoma versus squamous cell carcinoma of the vulva: A Japanese Gynecologic Oncology Group study
Shin Nishio, Koji Matsuo, Shinya Matsuzaki, Tomoyasu Kato, Shoji Kamiura, Hiroshi Adachi, Masao Okadome, Toshiaki Nakamura, Mikio Mikami, Takayuki Enomoto
Eur J Surg Oncol. 2021 Dec;47(12):3188-3193. doi: 10.1016/j.ejso.2021.07.002. Epub 2021 Jul 9.
- Clinico-pathological characteristics of patients with stage IB1-IB2 (FIGO 2018) uterine cervical cancer: a nationwide study in Japan
Keita Tsuji, Muneaki Shimada, Fumiaki Takahashi, Hideki Tokunaga, Imari Deura, Satoshi Yamaguchi, Toru Nakanishi, Koji Matsuo, Nobuo Yaegashi, Mikio Mikami
Int J Clin Oncol. 2021 Aug;26(8):1541-1552.
- Wait-time for adjuvant radiotherapy and oncologic outcome in early-stage cervical cancer: A treatment implication during the coronavirus pandemic
Matsuo K, Shimada M, Matsuzaki S, Enomoto T, Mikami M.
Eur J Cancer. 2021 Mar 17;148:117-120.
- A randomized phase III trial of adjuvant chemotherapy versus concurrent chemoradiotherapy for postoperative cervical cancer: Japanese Gynecologic Oncology Group study (JGOG1082)
Furusawa A, Takekuma M, Mori K, Usami T, Kondo E, Nishio S, Nishino K, Miyamoto Y, Yoshimura R, Watanabe M, Mikami M, Enomoto T
Int J Gynecol Cancer. 2021 Apr;31(4):623-626. doi: 10.1136/ijgc-2020-002344. Epub 2021 Mar 4.
- A retrospective assessment of the safety and efficacy of laparoscopic radical hysterectomy in Japan during the early years following its introduction: a Japanese Gynecologic Oncology Group study (JGOG1081S)
Kobayashi E, Kanao H, Takekuma M, Nishio S, Kojima‑Chiba A, Tozawa A, Yamaguchi S, Takeshima N, Nakatani E, Mikami M
Int J Clin Oncol. 2021 Feb;26(2):417-428.
- Hospital volume-outcome relationship in vulvar cancer treatment: a Japanese Gynecologic Oncology Group study
Matsuo K, Nishio S, Matsuzaki S, Machida H, Mikami M
J Gynecol Oncol. 2021 Mar;32(2):e24
- Surgical margin status and recurrence pattern in invasive vulvar Paget’s disease: A Japanese Gynecologic Oncology Group study
Matsuo K, Nishio S, Matsuzaki S, Iwase H, Kagami S, Soeda S , Usui H, Nishikawa R, Mikami M, Enomoto T
Gynecol Oncol. 2021 Mar;160(3):748-754
- Investigation of clinicopathological features of vulvar cancer in 1068 patients: A Japanese Gynecologic Oncology Group (JGOG) nationwide survey study
Nishio S, Murotani K, Nakao S, Takenaka M, Suzuki S, Aoki Y, Todo Y, Hosaka M, Nakai H, Katabuchi H, Nishi H, Takekuma M, Mikami M, Enomoto T
Gynecol Oncol. 2020 Aug 24;S0090-8258(20)33820-8. doi: 10.1016/j.ygyno.2020.08.019.
- Changes in the Clinicopathological Demographics of Vulvar Cancer in Japan: Increasing Oldest-Old, Stage Shifting, and Decreasing Cohort-Level Survival
Nishio S, Matsumoto K, Shibata T, Yamaguchi S, Kanao H, Takehara K, Kado N, Tozawa A, Tokunaga H, Matsunaga T, Kato H, Horie K, Kikuchi A, Enomoto T, Mikami M
J Clin Med. 2019 Nov 29;8(12):2081.
- Association of Radical Hysterectomy Surgical Volume and Survival for Early-Stage Cervical Cancer.
Matsuo K, Shimada M, Yamaguchi S, Matoda M, Nakanishi T, Kikkawa F, Ohmichi M, Okamoto A, Sugiyama T, Mikami M.
Obstet Gynecol. 2019 Jun;133(6):1086-1098.
- Significance of Malignant Peritoneal Cytology on the Survival of Women with Early-Stage Cervical Cancer:A Japanese Gynecologic Oncology Group Study
Matsuo K, Shimada M, Matsuzaki S, Machida H, Nagase Y, Saito T, Kamiura S, Iwata T, Sugiyama T, Mikami M.
J Clin Med. 2019 Nov 1;8(11):1822.
- Surgical Volume and Survival in Cervical Cancer: Bigger Is Better.
Rao GG
Obstet Gynecol. 2019 Jun;133(6):1084-1085.
- Prognostic significance of the number of pelvic lymph-nodes resection in patients with cervical adenocarcinoma: An analysis from JGOG 1070S study.
Ikeda Y, Kita T, Furusawa A, Takekuma M, Mikami M.
J Clin Oncol. 2019 May; 37(15 suppl) #5529
- Predictors for pathological parametrial invasion in clinical stage IIB cervical cancer.
Matsuo K, Shimada M Nakamura K, Takei Y, Ushijima K, Sumi T, Ohara T, Yahata H, Mikami M, Sugiyama T.
Eur J Surg Oncol. 2019 Aug;45(8):1417-1424. - Neoadjuvant Chemotherapy with Taxane and Platinum Followed by Radical Hysterectomy for Stage IB2-IIB Cervical Cancer: Impact of Histology Type on Survival.
Matsuo K, Shimada M, Yamaguchi S, Kigawa J, Tokunaga H, Tabata T, Kodama J, Kawana K, Mikami M, Sugiyama T
J Clin Med. 2019 Jan 30;8(2). pii: E156. doi: 10.3390/jcm8020156.
- Profile of treatment-related complications in women with clinical stage IB-IIB cervical cancer: A nationwide cohort study in Japan.
Machida H, Matsuo K, Furusawa A, Kita T, Kitagawa R, Mikami M.
PLoS One. 2019 Jan 7;14(1):e0210125. doi: 10.1371
- Postoperative chemotherapy for node-positive cervical cancer: Results of a multicenter phase II trial (JGOG1067).
Matoda M, Takeshima N, Michimae H, Iwata T, Yokota H, Torii Y, Yamamoto Y, Takehara K, Nishio S, Takano H, Mizuno M, Takahashi Y, Takei Y, Hasegawa T, Mikami M, Enomoto T, Aoki D, Sugiyama T.
Gynecol Oncol. 2018 Jun;149(3):513-519.
- Identifying a candidate population for ovarian conservation in young women with clinical stage IB-IIB cervical cancer.
Matsuo K, Shimada M, Yamaguchi S, Kanao H, Nakanishi T, Saito T, Kamiura S, Iwata T, Mikami M, Sugiyama T.
Int J Cancer. 2018 Mar 1;142(5):1022-1032.
- Effectiveness of adjuvant systemic chemotherapy for intermediate-risk stage IB cervical cancer.
Matsuo K, Shimada M, Yokota H, Satoh T, Katabuchi H, Kodama S, Sasaki H, Matsumura N, Mikami M, Sugiyama T.
Oncotarget 2017 Nov 15;8(63):106866-106875. doi: 10.18632/oncotarget.22437. eCollection 2017 Dec 5
- Risk stratification models for para-aortic lymph node metastasis and recurrence in stage IB-IIB cervical cancer.
Matsuo K, Shimada M, Tsuyoshi Saito T, Takehara K, Tokunaga H, Watanabe Y, Todo Y, Morishige K, Mikami M, Sugiyama T.
J Gynecol Oncol. 2018 Jan 29(1) e11.doi: 10.3802/jgo.2018.29.e11.
- The concept of platinum sensitivity could be applied to recurrent cervical cancer: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group.
Takekuma M, Mori K, Iida T, Kurihara K, Saitou M, Tokunaga H, Kawana K, Ikeda M, Satoh T, Saito T, Miyagi E, Nagai Y, Furusawa A, Kawano Y, Kawano K, Tabata T, Ota Y, Hayase R, Mikami M, Sugiyama T
Cancer Chemother Pharmacol. 2017 Oct;80(4):697-705.
- Ovarian conservation for young women with clinical stage IB-IIB cervical cancer in Japan.
Matsuo K, Shimada M, Mikami M.
J Gynecol Oncol. 2017 Jul;28(4):e60. doi: 10.3802/jgo.2017.28.e60.
- Comparison of adjuvant therapy for node-positive clinical stage IB-IIB cervical cancer: Systemic chemotherapy versus pelvic irradiation.
Matsuo K, Shimada M, Aoki Y, Sakamoto M, Takeshima N, Fujiwara H, Matsumoto T, Mikami M, Sugiyama T.
Int J Cancer. 2017 Sep;141(5):1042-1051.
- Human Papillomavirus Test for Triage of Japanese Women With Low-Grade Squamous Intraepithelial Lesions.
Iwata T, Hasegawa T, Ochiai K, Takizawa K, Umezawa S, Kuramoto H, Ohmura M, Kubushiro K, Arai H, Sakamoto M, Motoyama T, Watanabe K, Aoki D.
Reprod Sci. 2015 Dec;22(12):1509-15.
- シリーズで学ぶ最新知識 子宮頸がん臨床試験の最前線(1)GCIG 2014 Cervical Cancer Brainstorming Meeting in Melbourneの報告(1)
寒河江 悟. 戸板 孝文. 三上 幹男 他.
産婦人科の実際.2015.4; 64(4):549-554
- Surgical Principles for Managing Stage IB2, IIA2, and IIB Uterine Cervical Cancer (Bulky Tumors) in Japan: A Survey of the Japanese Gynecologic Oncology Group.
Mikami M, Aoki Y, Sakamoto M, Shimada M, Takeshima N, Fujiwara H, Matsumoto T, Kita T, Takizawa K; Disease Committee of Uterine Cervical and Vulvar Cancer, Japanese Gynecologic Oncology Group.
International Journal of Gynecological Cancer. 24(7):1333-40, 2014 Sep.
- Potential impact of combined high- and low-risk human papillomavirus infection on the progression of cervical intraepithelial neoplasia 2
Masao Okadome, Toshiaki Saito, Hideyuki Tanaka, Takayoshi Nogawa, Reiko Furuta, Kayoko Watanabe, Tsunekazu Kita, Kaichiro Yamamoto, Mikio Mikami, Ken Takizawa, Japanese Gynecologic Oncology Group (JGOG)
J Obstet Gynaecol Res. 2014 Feb;40(2):561-9. doi: 10.1111/jog.12202. Epub 2013 Oct 22.
- Phase III placebo-controlled double-blind randomized trial of radiotherapy for stage IIB-IVA cervical cancer with or without immunomodulator Z-100:a JGOG study
Sugiyama T, Fujiwara K, Ohashi Y, Yokota H, Hatae M, Ohno T, Nagai Y, Mitsuhashi N, Ochiai K, Noda K.
Annals of Oncology. 2014 May;25(5):1011-7
- Current surgical principle for uterine cervical cancer of stages Ia2, Ib1, and IIa1 in Japan: a survey of the Japanese Gynecologic Oncology Group.
Mikami M. Aoki Y. Sakamoto M. Shimada M. Takeshima N. Fujiwara H. Matsumoto T. Kita T. Takizawa K.
International Journal of Gynecological Cancer. 2013 Nov; 23(9): 1655-60; quiz 1661-2.
- Prospective evaluation of the Amplicor HPV test for predicting progression of cervical intraepithelial neoplasia 2
Takayoshi Nogawa, Masamichi Hiura, Hideyuki Tanaka, Toshiaki Saito, Reiko Furuta, Kayoko Watanabe, Tsunekazu Kita, Kaichiro Yamamoto, Mikio Mikami, Ken Takizawa, Japan Gynecologic Oncology Group
J Obstet Gynaecol Res. 2013 Aug;39(8):1347-53. doi: 10.1111/jog.12068. Epub 2013 Jul 2.
- Feasibility and Acute Toxicity of Concurrent Chemoradiotherapy (CCRT) With High-Dose Rate Intracavitary Brachytherapy (HDR-ICBT) and 40-mg/m2 Weekly Cisplatin for Japanese Patients With Cervical Cancer: Results of a Multi-Institutional Phase 2 Study (JGOG1066).
Toita T, Kitagawa R, Hamano T, Umayahara K, Hirashima Y, Aoki Y, Oguchi M, Mikami M, Takizawa K; Cervical Cancer (Vulva Cancer) Committee of the Japanese Gynecologic Oncology Group (JGOG).
Int J Gynecol Cancer. 2012; 22: 1420-26.
- Phase II study of neoadjuvant chemotherapy with irinotecan hydrochloride and nedaplatin followed by radical hysterectomy for bulky stage Ib2 to IIb, cervical squamous cell carcinoma: Japanese Gynecologic Oncology Group study (JGOG 1065).
Yamaguchi S, Nishimura R, Yaegashi N, Kiguchi K, Sugiyama T, Kita T, Kubushiro K, Kokawa K, Hiura M, Mizutani K, Yamamoto K, Takizawa K.
Oncol Rep. 2012; 28: 487-93.
- Phase II study of concurrent chemoradiotherapy with high-dose-rate intracavitary brachytherapy in patients with locally advanced uterine cervical cancer: Efficacy and toxicity of a low cumulative radiation dose schedule.
Toita T, Kitagawa R, Hamano T, Umayahara K, Hirashima Y, Aoki Y, Oguchi M, Mikami M, Takizawa K; Cervical Cancer (Vulva Cancer) Committee of the Japanese Gynecologic Oncology Group (JGOG).
Gynecol Oncol. 2012; 126: 211-6.
- Radiotherapy quality assurance of the Japanese Gynecologic Oncology Group study (JGOG1066): a cooperative phase II study of concurrent chemoradiotherapy for uterine cervical cancer.
Toita T, Kato S, Ishikura S, Tsujino K, Kodaira T, Uno T, Hatano K, Sakurai H, Niibe Y, Kazumoto T, Nishimura T, Kitagawa R, Fukutani M, Oguchi M, Umayahara K, Hirashima Y, Aoki Y, Takizawa K; and Disease Committee of Radiation Oncology, Japanese Gynecologic Oncology Group.
Int J Clin Oncol. 2011; 16 : 379-86.
- Phase I study of combination chemotherapy with irinotecan hydrochloride and nedaplatin for cervical squamous cell carcinoma: Japanese gynecologic oncology group study.
Yamamoto K, Kokawa K, Umesaki N, Nishimura R, Hasegawa K, Konishi I, Saji F, Nishida M, Noguchi H, Takizawa K.
Oncol Rep. 2009; 21: 1005-9.
- Phase I study of irinotecan combined with mitomycin- C and 5-fluorouracil for gynecological malignancies; The JGOG Study.
Kokawa K, Umesaki N, Yamamoto K, Takizawa K, Konishi I, Hasegawa K; Japan Gynecologic Oncology Group.
Anticancer Res. 2008; 28: 2933-9.
- Adjuvant oral 5-fluorouracil for cervical cancer: Japanese Gynecologic Oncology Group report.
Yamamoto K, Izumi R, Hasegawa K, Nakajima H, Ohashi K, Kudo R, Okuda H, Takahashi T, Origasa H, Sugimori H.
Int J Oncol. 2004; 24: 1175-9.
- Phase II study of irinotecan combined with mitomycin-C for advanced or recurrent squamous cell carcinoma of the uterine cervix: the JGOG study.
Umesaki N, Fujii T, Nishimura R, Tanaka T, Nishida M, Fushiki H, Takizawa K, Yamamoto K, Hasegawa K, Izumi R; Japan Gynecologic Oncology Group.
Gynecol Oncol. 2004; 95: 127-32.
- 進行・再発子宮頸癌に対するBOMP療法の効果（子宮頸がん第5次特定研究DS-1）．
梅咲直彦、野口浩、伏木弘、西田正人、奥田博之、滝澤憲、宇田川康博、山本嘉一郎、長谷川和男、泉陸一．
第18回婦人科がん化学療法共同研究会記録集 23-7, 2001
- 進行および再発子宮頸部腺癌に対するMEP療法の効果．
梅咲直彦、泉陸一、宇田川康博、奥田博之、河野一郎、杉森甫、滝澤憲、西田正人、長谷川和男、伏木弘、山本嘉一郎、野田起一郎、田中哲二．
Oncol Chemother.182-6, 2000
- Cervical adenocarcinoma, a novel combination chemotherapy with mitomycin C, etoposide, and cisplatin for advanced or recurrent disease.
Umesaki N, Izumi R, Fushiki H, Hasegawa K, Kono I, Nishida M, Noguchi H, Okuda H, Sugimori H, Takizawa K, Udagawa Y, Yamamoto K, Tanaka T, Noda K.
Gynecol Oncol.1999; 75: 142-4.
- Practice patterns of adjuvant therapy for intermediate/high recurrence risk cervical cancer patients in Japan.
Ikeda Y, Furusawa A, Kitagawa R, Tokinaga A, Ito F, Ukita M, Nomura H, Yamagami W, Tanabe H, Mikami M, Takeshima N, Yaegashi N.
J Gynecol Oncol. 2016 May;27(3):e29.
- Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial
Nicoletta Colombo,Elena Biagioli, Kenichi Harano,Francesca Galli,Emma Hudson,Yoland Antill,et al.
August 02, 2024DOI:https://doi.org/10.1016/S1470-2045(24)00334-6
- Pretreatment systemic inflammatory markers predict survival in endometrial cancer: A Japanese Gynecologic Oncology Group 2043 exploratory data analysis
Shin Nishio, Kenta Murotani, Wataru Yamagami, Shiro Suzuki, Hidekatsu Nakai, Kazuyoshi Kato, Hideki Tokunaga, Hiroyuki Nomura, Yoshihito Yokoyama, Kazuhiro Takehara, Aikou Okamoto
Gynecol Oncol. 2024 Feb:181:46-53. doi: 10.1016/j.ygyno.2023.12.007. Epub 2023 Dec 19.
- JGOG2046: a feasibility study of neoadjuvant chemotherapy followed by debulking surgery for clinically diagnosed FIGO stage IVb endometrial cancer
Toru Nakanishi, Toshiaki Saito, Daisuke Aoki, Yo Watanabe, Kimio Ushijima, Masashi Takano, Toru Sugiyama, Nobuo Yaegashi, Kazuhiro Takehara
Int J Clin Oncol. 2023 Mar;28(3):436-444. doi: 10.1007/s10147-022-02284-9. Epub 2023 Feb 2.
- Phase II study of niraparib in recurrent or persistent rare fraction of gynecologic malignancies with homologous recombination deficiency (JGOG2052)
Hiroshi Asano, Katsutoshi Oda, Kosuke Yoshihara, Yoichi M Ito, Noriomi Matsumura, Muneaki Shimada, Hidemichi Watari, Takayuki Enomoto
J Gynecol Oncol. 2022 Jul;33(4):e55. doi: 10.3802/jgo.2022.33.e55. Epub 2022 May 3.
- Clinical Status and Prognostic Factors in Japanese Patients With Uterine Leiomyosarcoma
Kazuhiro Takehara, Natsumi Yamashita, Reiko Watanabe, Norihiro Teramoto, Hitoshi Tsuda, Takashi Motohashi, Kenichi Harano, Toru Nakanishi, Hideki Tokunaga, Nobuyuki Susumu, Yutaka Ueda, Yoshihito Yokoyama, Toshiaki Saito
Gynecol Oncol, 157 (1), 115-120 Apr 2020
- Analysis of the relapse patterns and risk factors of endometrial cancer following postoperative adjuvant chemotherapy in a phase III randomized clinical trial.
Nomura H, Aoki D, Susumu N, Mizuno M, Nakai H, Arai M, Nishio S, Tokunaga H, Nakanishi T, Watanabe Y, Yaegashi N, Yokoyama Y, Takehara K.
Gynecol Oncol. 2019 Dec;155(3):413-419.
- Effect of Taxane Plus Platinum Regimens vs Doxorubicin Plus Cisplatin as Adjuvant Chemotherapy for Endometrial Cancer at a High Risk of Progression: A Randomized Clinical Trial.
Nomura H, Aoki D, Michimae H, Mizuno M, Nakai H, Arai M, Sasagawa M, Ushijima K, Sugiyama T, Saito M, Tokunaga H, Matoda M, Nakanishi T, Watanabe Y, Takahashi F, Saito T, Yaegashi N
JAMA Oncol. 2019 Jun 1;5(6):833-840.
- Optimal cytoreductive surgery in patients with advanced uterine carcinosarcoma: A multi-institutional retrospective study from the Japanese gynecologic oncology group.
Harano K, Hirakawa A, Yunokawa M, Nakamura T, Satoh T, Nishikawa T, Aoki D, Ito K, Ito K, Nakanishi T, Susumu N, Takehara K, Watanabe Y, Watari H, Saito T.
Gynecol Oncol. 2016 Jun;141(3):447-453.
- How do Japanese gynecologists view hormone replacement therapy for survivors of endometrial cancer? Japanese Gynecologic Oncology Group (JGOG) survey.
Yokoyama Y, Ito K, Takamatsu K, Takehara K, Nakanishi T, Harano K, Watari H, Susumu N, Aoki D, Saito T.
Int J Clin Oncol. 2015 Oct;20(5):997-1004. doi: 10.1007/s10147-015-0808-5. Epub 2015 Mar 6.
- Prognostic factors in patients with uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group.
Harano K, Hirakawa A, Yunokawa M, Nakamura T, Satoh T, Nishikawa T, Aoki D, Ito K, Ito K, Nakanishi T, Susumu N, Takehara K, Watanabe Y, Watari H, Saito T.
Int J Clin Oncol. 2015 Jun 18.
- Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group study (JGOG2041).
Nomura H, Aoki D, Takahashi F, Katsumata N, Watanabe Y, Konishi I, Jobo T, Hatae M, Hiura M, Yaegashi N.
Ann Oncol. 2011; 22: 636-42.
- Practice pattern for postoperative management of endometrial cancer in Japan: a survey of the Japanese Gynecologic Oncology Group(JGOG2044s).
Watanabe Y, Kitagawa R, Aoki D, Takeuchi S, Sagae S, Sakuragi N, Yaegashi N; Disease Committee of Uterine Endometrial Cancer, Japanese Gynecologic Oncology Group.
Gynecol Oncol. 2009; 115: 456-9.
- Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study.
Susumu N, Sagae S, Udagawa Y, Niwa K, Kuramoto H, Satoh S, Kudo R; Japanese Gynecologic Oncology Group.
Gynecol Oncol. 2008; 108: 226-33.
- Status of surgical treatment procedures for endometrial cancer in Japan: results of a Japanese Gynecologic Oncology Group survey.（JGOG2045s）
Watanabe Y, Aoki D, Kitagawa R, Takeuchi S, Sagae S, Sakuragi N, Yaegashi N; Disease Committee of Uterine Endometrial Cancer, Japanese Gynecologic Oncology Group.
Gynecol Oncol. 2007; 105: 325-8.
- 子宮体がん化学療法第三次研究の最終解析成績．
佐藤信二、野澤志朗、宇田川康博、丹羽憲司、寒河江悟、工藤隆一、蔵本博行、西谷巖．
第17回婦人科がん化学療法共同研究会記録集22-7, 2000
- 子宮体がん化学療法第2次研究の最終解析成績．
佐藤信二、矢嶋聰、野澤志朗、宇田川康博、寺島芳輝、西谷巖、小澤満、工藤隆一、蔵本博行、岡田弘二．
Oncol Chemother.12(Suppl): 14-20, 1996
- 子宮体癌に対する補助化学療法および寛解導入療法 子宮体がん化学療法第一次研究．
佐藤信二、矢嶋聰、野澤志朗、宇田川康博、寺島芳輝、西谷巖、小澤満、工藤隆一、蔵本博行、岡田弘二．
Oncol Chemother.11: 188-197, 1995
- Heterogeneous treatment effect of dose-dense paclitaxel plus carboplatin therapy for advanced ovarian cancer
Ayumi Taguchi, Kosuke Kato, Akiko Furusawa, Konan Hara, Kenbun Sone, Kyosuke Yamada, Hiroaki Kajiyama, Muneaki Shimada, Aikou Okamoto
Int J Cancer. 2024 Sep 15;155(6):1068-1077. doi: 10.1002/ijc.34996. Epub 2024 May 7.
- Artificial intelligence-based histopathological subtyping of high-grade serous ovarian cancer
Akihiko Ueda, Hidekatsu Nakai, Chiho Miyagawa, Tomoyuki Otani, Manabu Yoshida, Ryusuke Murakami, Shinichi Komiyama, Terumi Tanigawa, Takeshi Yokoi, Hirokuni Takano, Tsukasa Baba, Kiyonori Miura, Muneaki Shimada, Junzo Kigawa, Takayuki Enomoto, Junzo Hamanishi, Aikou Okamoto, Yasushi Okuno, Masaki Mandai, Noriomi Matsumura
Am J Pathol. 2024 Jul 18:S0002-9440(24)00243-8. doi: 10.1016/j.ajpath.2024.06.010. Online ahead of print.
- Intraperitoneal Carboplatin for Ovarian Cancer - A Phase 2/3 Trial.
Nagao S, Fujiwara K, Yamamoto K, Tanabe H, Okamoto A, Takehara K, Saito M, Fujiwara H, Tan DSP, Yamaguchi S, Adachi S, Kikuchi A, Hirasawa T, Yokoi T, Nagai T, Sato T, Kamiura S, Fujishita A, Loong WW, Chan K, Syks P, Olawaye A, Ryu SY, Shigeta H, Kondo E, Yokoyama Y, Matsumoto T, Hasegawa K, Enomoto T
NEJM Evid. 2023 May;2(5):EVIDoa2200225. doi: 10.1056/EVIDoa2200225. Epub 2023 Apr 21.PMID: 38320049 Clinical Trial.
- Randomized phase III trial comparing pegylated liposomal doxorubicin (PLD) at 50 mg/m² versus 40 mg/m² in patients with platinum-refractory and -resistant ovarian carcinoma: the JGOG 3018 Trial.
Motohashi T, Yabuno A, Michimae H, Ohishi T, Nonaka M, Takano M, Nishio S, Fujiwara H, Fujiwara K, Kondo E, Sugiyama T, Tabata T
J Gynecol Oncol. 2021 Jan;32(1):e9. doi: 10.3802/jgo.2021.32.e9. Epub 2020 Nov 10.PMID: 33185050 Free PMC article. Clinical Trial.
- Heterogeneous treatment effect of dose-dense paclitaxel plus carboplatin therapy for advanced ovarian cancer
Ayumi Taguchi, Kosuke Kato, Akiko Furusawa, Konan Hara, Kenbun Sone, Kyosuke Yamada, Hiroaki Kajiyama, Muneaki Shimada, Aikou Okamoto
Int J Cancer. 2024 May 7. doi: 10.1002/ijc.34996. Online ahead of print.
- Homologous recombination inquiry through ovarian malignancy investigations: JGOG3025 Study
Kosuke Yoshihara, Tsukasa Baba, Hideki Tokunaga, Koji Nishino, Masayuki Sekine, Shiro Takamatsu, Noriomi Matsumura, Hiroshi Yoshida, Hiroaki Kajiyama, Muneaki Shimada, Tatsuo Kagimura, Katsutoshi Oda, Yuko Sasajima, Nobuo Yaegashi, Aikou Okamoto, Toru Sugiyama, Takayuki Enomoto
Cancer Sci. 2023 Feb 6. doi: 10.1111/cas.15747. Online ahead of print.
- An attempt to establish real-world databases of poly(ADP-ribose) polymerase inhibitors for advanced or recurrent epithelial ovarian cancer: the Japanese Gynecologic Oncology Group
Muneaki Shimada, Kosuke Yoshihara, Terumi Tanigawa, Hiroyuki Nomura, Junzo Hamanishi, Satoe Fujiwara, Hiroshi Tanabe, Hiroaki Kajiyama, Masaki Mandai, Daisuke Aoki, Takayuki Enomoto, and Aikou Okamoto
J Gynecol Oncol. 2023 May;34(3):e62. English.Published online Apr 21, 2023.
- Phase 2 single-arm study on the efficacy and safety of niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer
Aikou Okamoto, Eiji Kondo, Toshiaki Nakamura, Satoshi Yanagida, Junzo Hamanishi, Kenichi Harano, Kosei Hasegawa, Takeshi Hirasawa, Kensuke Hori, Shinichi Komiyama, Motoki Matsuura, Hidekatsu Nakai , Hiroko Nakamura , Jun Sakata , Tsutomu Tabata , Kazuhiro Takehara, Munetaka Takekuma, Yoshihito Yokoyama, Yoichi Kase , Shuuji Sumino, Junpei Soeda, Ajit Suri , Daisuke Aoki , Toru Sugiyama
J Gynecol Oncol. 2021 Mar;32(2):e16. doi: 10.3802/jgo.2021.32.e16. Epub 2020 Dec 10.
- The post-progression survival of patients with recurrent or persistent ovarian clear cell carcinoma: results from a randomized phase III study in JGOG3017/GCIG
Eiji Kondo, Tsutomu Tabata, Nao Suzuki, Daisuke Aoki, Hideaki Yahata, Yoshio Kotera, Osamu Tokuyama, Keiichi Fujiwara, Eizo Kimura, Fumitoshi Terauchi, Toshiyuki Sumi, Aikou Okamoto, Nobuo Yaegashi, Takayuki Enomoto, Toru Sugiyama
J Gynecol Oncol. 2020 Nov;31(6):e94.
- Efficacy and safety of standard of care with/without bevacizumab for platinum-resistant ovarian/fallopian tube/peritoneal cancer previously treated with bevacizumab: The Japanese Gynecologic Oncology Group study JGOG3023
Tadahiro Shoji, Takayuki Enomoto, Masakazu Abe, Aikou Okamoto, Takayuki Nagasawa, Tetsuro Oishi, Satoru Nagase, Masahiko Mori, Yuki Inokuchi, Shoji Kamiura, Shinichi Komiyama, Nobuhiro Takeshima, Toru Sugiyama
Cancer Sci. 2022 Jan;113(1):240-250. doi: 10.1111/cas.15185. Epub 2021 Nov 18.
- Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer: A Systematic Review and Meta-analysis.
Paoletti X, Lewsley LA, Daniele G, Cook A, Yanaihara N, Tinker A, Kristensen G, Ottevanger PB, Aravantinos G, Miller A, Boere IA, Fruscio R, Reyners AKL, Pujade-Lauraine E, Harkin A4, Pignata S, Kagimura T, Welch S, Paul J4, Karamouza E, Glasspool RM; Gynecologic Cancer InterGroup (GCIG) Meta-analysis Committee.
JAMA Netw Open. 2020 Jan 3;3(1):e1918939. doi: 10.1001/jamanetworkopen.2019.18939.
- The mesenchymal transition subtype more responsive to dose dense taxane chemotherapy combined with carboplatin than to conventional taxane and carboplatin chemotherapy in high grade serous ovarian carcinoma: A survey of Japanese Gynecologic Oncology Group study (JGOG3016A1).
Murakami R, Matsumura N, Michimae H, Tanabe H, Yunokawa M, Iwase H, Sasagawa M, Nakamura T,Tokuyama O, Takano M, Sugiyama T, Sawasaki T, Isonishi S, Takehara K, Nakai H, Okamoto A, Mandai M, Konishi I.
Gynecol Oncol. 2019 May;153(2):312-319. doi: 10.1016/j.ygyno.2019.02.010. Epub 2019 Mar 8.
- An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023.
Shoji T, Komiyama S, Kigawa J, Tanabe H, Kato K, Itamochi H, Fujiwara H, Kamiura S, Hamano T, Sugiyama T,
BMC Cancer. 2018 Jul 31;18(1):771. doi: 10.1186/s12885-018-4505-4.
(BMC Cancer) (PubMed) - Bevacizumab combined with platinum–taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial)
Komiyama S, Kato K, Inokuchi Y, Takano H, Matsumoto T, Hongo A, Asai-Sato M, Arakawa A, Kamiura S, Tabata T, Takeshima N, Sugiyama T,
Int J Clin Oncol. 2019 Jan;24(1):103-114.
- Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial.
Sugiyama T, Okamoto A, Enomoto T, Hamano T, Aotani E, Terao Y, Suzuki N, Mikami M, Yaegashi N, Kato K, Yoshikawa H, Yokoyama Y, Tanabe H, Nishino K, Nomura H, Kim JW, Kim BG, Pignata S, Alexandre J, Green J, Isonishi S, Terauchi F, Fujiwara K, Aoki D.
J Clin Oncol. 2016 Aug 20;34(24):2881-7. doi: 10.1200/JCO.2016.66.9010. Epub 2016 Jul 11.
- Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016).
Harano K. Terauchi F. Katsumata N. Takahashi F. Yasuda M. Takakura S. Takano M. Yamamoto Y. Sugiyama T..
Annals of Oncology. 2014 Jan; 25(1): 251-7.
- Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial.
Katsumata N. Yasuda M. Isonishi S. Takahashi F. Michimae H. Kimura E. Aoki D. Jobo T. Kodama S. Terauchi F. Sugiyama T. Ochiai K.
Lancet Oncology. 2013 Sep; 14(10): 1020-6.
- Docetaxel/irinotecan combination chemotherapy in platinum/taxane-refractory and -resistant ovarian cancer: JGOG/WJGOG Intergroup Study.
Ushijima K. Kamura T. Tamura K. Kuzuya K. Sugiyama T. Noda K. Ochiai K.
International Journal of Clinical Oncology. 2013 Feb; 18(1): 126-31.doi: 10.1007/s10147-011-0353-9. Epub 2011 Nov 30.
- Does severe anemia caused by dose-dense paclitaxel-Carboplatin combination therapy have an effect on the survival of patients with epithelial ovarian cancer? Retrospective analysis of the Japanese gynecologic oncology group 3016 trial.
Kumagai S, Sugiyama T, Shoji T, Michimae H, Katsumata N, Aoki D, Terauchi F, Jobo T, Ochiai K, Yasuda M.
Int J Gynecol Cancer. 2011; 21: 1585-91.
- Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study.
Takakura S, Takano M, Takahashi F, Saito T, Aoki D, Inaba N, Noda K, Sugiyama T, Ochiai K; Japanese Gynecologic Oncology Group.
Int J Gynecol Cancer. 2010; 20: 240-7.
- Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial.
Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, Tsuda H, Sugiyama T, Kodama S, Kimura E, Ochiai K, Noda K; Japanese Gynecologic Oncology Group.
Lancet. 2009; 374: 1331-8.
- Phase II clinical trial of pegylated liposomal doxorubicin (JNS002) in Japanese patients with mullerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of fallopian tube, peritoneal carcinoma) having a therapeutic history of platinum-based chemotherapy: a Phase II Study of the Japanese Gynecologic Oncology Group.
Katsumata N, Fujiwara Y, Kamura T, Nakanishi T, Hatae M, Aoki D, Tanaka K, Tsuda H, Kamiura S, Takehara K, Sugiyama T, Kigawa J, Fujiwara K, Ochiai K, Ishida R, Inagaki M, Noda K.
Jpn J Clin Oncol. 2008; 38: 777-85.
- RANDOMIZED TRIAL ON ADJUVANT IV CHEMOTHERAPY CDDP + CPA VERSUS PO CHEMOTHERAPY CPA FOR STAGE IA OVARIAN CANCER BY THE JAPANESE GYNECOLOGIC ONCOLOGY AND CHEMOTHERAPY STUDY GROUP (Meeting abstract).
Hatae M, Onishi Y, Noda K, Yakushiji M, Ozaki K, Ochiai K, Kuzuya K, Takahashi T, Tateno M, Yoshikawa H, Nishida T.
1998 ASCO Annual Meeting Abstract No: 1412
- Protocol for a Prospective Cohort Study to Evaluate Changes in Sexuality in Patients With Primary Cervical Cancer Using Patient-Reported Outcomes (JGOG9004, SARAH Study), and Our Approaches to Solving the Unmet Needs of Patients With Gynecological Cancer
Hitomi Sakai, Yoshio Itani, Yoichi Kobayashi, Mikiko Asai-Sato, Kazuto Tasaki, Shoji Nagao, Masayuki Futagami, Makoto Yamamoto, Etsuko Fujimoto, Yuji Ikeda, Megumi Yokota, Nobutaka Hayashi, Motoki Matsuura, Takayuki Nagasawa, Yumi Ishidera, Shinya Sato, Tetsutaro Hamano, Nao Suzuki, Yoshio Yoshida
J Clin Gynecol Obstet. 2023;12(2):59-64
- Comparison of older and younger patients with ovarian cancer: A post hoc study (JGOG3016-A3) of the treatment strength and prognostic outcomes of conventional or dose-dense chemotherapy
Yoshio Itani, Hitomi Sakai, Tetsutaro Hamano, Mikiko Asai-Sato, Masayuki Futagami, Masaki Fujimura, Yoichi Aoki, Nao Suzuki, Yoshio Yoshida, Takayuki Enomoto
J Obstet Gynaecol Res. 2023 May;49(5):1400-1411. doi: 10.1111/jog.15620. Epub 2023 Mar 1.
- Perceptions and practice patterns of cancer survivorship care among Japanese gynecologic oncologists: The JGOG questionnaire survey
Mikiko Asai-Sato, Nao Suzuki, Hitomi Sakai, Yoshio Itani, Shinya Sato, Masayuki Futagami, Yoshio Yoshida
J Gynecol Oncol. 2023 Jan;34(1):e10. doi: 10.3802/jgo.2023.34.e10. Epub 2022 Oct 26.
- Prognostic relevance of HRDness gene expression signature in ovarian high-grade serous carcinoma; JGOG3025-TR2 study
Shiro Takamatsu, Kosuke Yoshihara, Tsukasa Baba, Muneaki Shimada, Hiroshi Yoshida, Hiroaki Kajiyama, Katsutoshi Oda, Masaki Mandai, Aikou Okamoto, Takayuki Enomoto, and Noriomi Matsumura
Br J Cancer. 2023 Apr;128(6):1095-1104. doi: 10.1038/s41416-022-02122-9. Epub 2023 Jan 2.
- Current treatment strategies for ovarian cancer in the East Asian Gynecologic Oncology Trial Group (EAGOT)
Yusuke Kobayashi, Muneaki Shimada, Masato Tamate, Hyun Woong Cho, Jun Zhu, Hung-Hsueh Chou, Hiroaki Kajiyama, Aikou Okamoto, Daisuke Aoki, Sokbom Kang, Jeong-Won Lee, Jae-Weon Kim, Jae-Hoon Kim, Zhongqiu Lin, Jihong Liu, Xiaohua Wu, Hung-Cheng Lai, Ting-Chang Chang, Chyong-Huey Lai, Yong Man Kim, and Takayuki Enomoto
J Gynecol Oncol. 2024 May;35(3):e87. doi: 10.3802/jgo.2024.35.e87. Epub 2024 Apr 3.
- Transitional dynamics in oncology clinical trials: evaluating the impact of Clinical Trials Act on cooperative groups
Kenichi Nakamura, Koji Takeda, Akiko M Saito, Miho Kato, Shinya Sato, Satoshi Nakagawa, Yasuyuki Kawamoto, Eiji Oki, Isamu Okamoto, Hiroaki Okamoto, Hiroshi Katayama, Junki Mizusawa, Harumi Kaba, Taro Shibata, Haruhiko Fukuda
Japanese Journal of Clinical Oncology, hyae034, https://doi.org/10.1093/jjco/hyae034
